Brand Name or Equal MedTrack Database Licenses for Five (5) Users

The purpose of this amendment is to define the period of performance as follows:

Base Period: September 17, 2015 - September 16, 2016
Option Period One: September 17, 2016 - September 16, 2017
Option Period Two: September 17, 2017 - September 16, 2018

----------------------------------------------------------------------------------------

This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. N02CO52661-85 includes all applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2005-81, simplified procedures for commercial items.

This acquisition will be conducted under the procedures for acquiring commercial items authorized in FAR Part 12 and under the authority to use simplified procedures for commercial requirements as provided in FAR 13.501.

This requirement is assigned North American Industry Classification System (NAICS) code 541519 with a size standard of $25 Million is being considered.

Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. THIS IS A TOTAL SMALL BUSINESS SET - ASIDE.

BACKGROUND
The U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI), Office of the Director (OD), Technology Transfer Center (TTC), plans to procure Brand Name or Equal MedTrack Database Licenses for five (5) users.

The mission of the TTC Marketing Group is to locate potential collaboration partners that would be interested in developing research discoveries from the NIH Intramural Research Program; to conduct due diligence on potential partners; and to understand the landscape of a wide variety of drug development efforts. TTC therefore requires access to timely data that describe the relative importance of different inventions and patents, and whether the cost of patenting them will be worth the time, effort, and costs. An integrated application is needed to aggregate the wide variety of database information sources.

The salient characteristics that apply to this acquisition are as follows:

• Comprehensive, integrated platform provides the development pipelines of small, medium, and large domestic and international pharmaceutical and biotechnology companies;
• Provides information to relevant business development, competitive intelligence, marketing, market research, and valuations;
• Provides unlimited, on-demand research support;
• Provides unlimited technical support within 24 hours;
• Provides unlimited, on-demand training;
• Provides unlimited, customizable watch lists and email alerts to monitor development activities across all of the aggregated platforms;
• Integrated platform provides unique capability to search across different databases simultaneously:
  o Past, present and forecasted sales of products-- can provide valuation
  estimates of NIH discoveries;
  o Proprietary royalty database indicates royalties paid on licensed products--
  can enable TTC to estimate the valuation of NIH discoveries;
  o Companies' spending on research and development;
  o Companies' intellectual property such as patents;
  o Deals such as collaborations, mergers, and acquisitions;
  o Start-up companies' venture financing, grants, and contracts;
  o Therapeutics' modes of action, mechanisms of action, composition and
  structure, brand and generic names, biological targets, clinical trial
  information, and development history;
  o For due diligence, can investigate potential licensee history, including
  finances, investments, existing partnerships, management and their
  experience, IP portfolio, and drug pipeline (developmental, marketed,
  withdrawn drugs).
• Estimate valuations of NIH developmental drugs based on companies' financing rounds, public offerings, and disclosed financials
• Scheduled clinical trial and regulatory milestones, patent expiries, and sales forecasts for estimating a product's sales and royalties;
• Epidemiology studies that describe diseases, size and distribution of markets, and current and developing therapies for those diseases;
• Contains contact information and biographies of company managers and executives;
• The data is updated real-time;
• The user interface is easy to learn, with a Basic Search feature that is important for quick searches or for new users;
• A multi-tier, menu-driven Advanced Search integrates many different functions and search fields from multiple databases;
• Broad coverage of the patents behind current and in-development pharmaceutical and biotechnology products, and this is helpful in finding partners;
• Visualization of large, complex datasets to identify trends and relationships, and create dynamic timelines of drug development

PAYMENT
Payment shall be made upon the delivery and acceptance of all required items.

CONTRACT CLAUSES/PROVISIONS
The following Federal Acquisition Regulation and Health & Human Services Acquisition
Regulation Provisions/Clauses apply to this acquisition:

FAR 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): http://www.acquisition.gov/far/ and/or http://www.hhs.gov/policies/hhsar/.

FAR 52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS (APR
2014)

FAR 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-
COMMERCIAL ITEMS (MAR 2015)

FAR 52.212-4 CONTRACT TERMS AND CONDITIONS-COMMERCIAL
ITEMS (MAY 2015)

HHSAR 352.222-70 CONTRACTOR COOPERATION IN EQUAL
EMPLOYMENT OPPORTUNITY (JAN 2010)

HHSAR 352.242-71 TOBACCO-FREE FACILITIES (JAN 2006)

FAR 52.212-5 CONTRACT TERMS AND CONDITIONS REQUIRED TO
IMPLEMENT STATUTES OR EXECUTIVE ORDERS-
COMMERCIAL ITEMS (MAY 2015).

The following FAR clauses cited in paragraph (b) of the clause at FAR 52.212-5 are also applicable to this acquisition:

FAR Clause 52.203-6 Restrictions on Subcontractor Sales to the Government
FAR Clause 52.203-13 Contractor Code of Business Ethics and Conduct
FAR Clause 52.204-10 Reporting Executive Compensation and First Tier Subcontract
Awards
FAR Clause 52.209-6 Protecting the Government's Interest When Subcontracting with
Contractors Debarred, Suspended, or Proposed for Debarment
FAR Clause 52.209-9 Updates of Publicly Available Information Regarding
Responsibility
FAR Clause 52.219-6 Notice of Total Small Business Set-Aside
FAR Clause 52.219-8 Utilization of Small Business Concerns
FAR Clause 52.219-28 Post Award Small Business Program Representation
FAR Clause 52.222-3 Convict Labor
FAR Clause 52.222-19 Child Labor-Cooperation with Authorities and Remedies
FAR Clause 52.222-21 Prohibition of Segregated Facilities
FAR Clause 52.222-26 Equal Opportunity
FAR Clause 52.222-35 Equal Opportunity for Special Disabled Veterans, Veterans of
the Vietnam Era, and Other Eligible Veterans
FAR Clause 52.222-36 Affirmative Action for Workers with Disabilities
FAR Clause 52.222-37 Employment Reports of Special Disabled Veterans, Veterans of
the Vietnam Era, and Other Eligible Veterans
FAR Clause 52.222-40 Notification of Employee Rights Concerning Payment of Union
Dues or Fees
FAR Clause 52.223-18 Encouraging Contractor Policies to Ban Text Messaging while
Driving
FAR Clause 52.225-5 Trade Agreements
FAR Clause 52.225-13 Restrictions on Certain Foreign Purchases
Far Clause 52.232-33 Payment by Electronic Funds Transfer-System for Award
Management
FAR Clause 52.247-64 Preference for Privately Owned U.S.-Flag Commercial Vessels

FAR 52.211-6 BRAND NAME OR EQUAL (AUG 1999)

(a) If an item in this solicitation is identified as "brand name or equal," the purchase description reflects the characteristics and level of quality that will satisfy the Government's needs. The salient physical, functional, or performance characteristics that "equal" products must meet are specified in the solicitation.
(b) To be considered for award, offers of "equal" products, including "equal" products of the brand name manufacturer, must-(1) Meet the salient physical, functional, or performance characteristic specified in this solicitation;
(2) Clearly identify the item by-
(i) Brand name, if any; and
(ii) Make or model number;
(3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and
(4) Clearly describe any modification the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modification.
(c) The Contracting Officer will evaluate "equal" products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer.
(d) Unless the offeror clearly indicates in its offer that the product being offered is an "equal" product, the offeror shall provide the brand name product referenced in the solicitation.

HHSAR 352.203-70 ANTI-LOBBYING (MAR 2012)

Pursuant to the current HHS annual appropriations act, Public Law 112-74, except for normal and recognized executive-legislative relationships, the Contractor shall not use any HHS contract funds for:

(a)Publicity or propaganda purposes;
(b)The preparation, distribution, or use of any kit, pamphlet, booklet, publication, electronic communication, radio, television or video presentation designed to support or defeat the enactment of legislation before the Congress or any State or local legislature or legislative body, except in presentation to the Congress or any State or local legislature itself; or designed to support of defeat any proposed or pending regulation, administrative action, or order issued by the executive branch of any State or local government, except in presentation to the executive branch of any State or local government itself; or
(c)Payment of salary or expenses of the Contractor, or any agent acting for the Contractor, related to any activity designed to influence the enactment of legislation, appropriations regulation, administrative action, or Executive order proposed or pending before the Congress or any State government, State legislature or local legislature or legislative body, other than for normal and recognized executive-legislative relationships or participation by an agency or officer of a State, local or tribal government is policymaking and administrative processes within the executive branch of that government.

The prohibitions in subsections (a), (b), and (c) above shall include any activity to advocate or promote any proposed, pending, or future Federal, State or local tax increase, or any proposed, pending, or future requirement for, or restriction on, any legal consumer product, including its sale or marketing, including, but not limited to, the advocacy or promotion of gun control.

SUBMISSION INFORMATION
Proposals must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of valid certification in the System for Award Management (SAM) at www.sam.gov.

Questions must be submitted electronically (via email) to Contract Specialist, Megan Kisamore, at megan.kisamore@nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than Monday, August 17, 2015, 11:00 am, EST.

Proposals must be submitted electronically (via email) to Contract Specialist, Megan Kisamore, at megan.kisamore@nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than Monday, August 24, 2015, 11:00 am, EST. All responses must be received by the specified due date and time in order to be considered. PROPOSALS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. No collect calls will be accepted.

Please refer to solicitation no: N02CO52661-85 on all correspondence.

EVALUATION
The award decision will be based on a Lowest Price Technically Acceptable (LPTA) determination. Award will be made on all or none basis. If you are providing an "equal" product, you must submit additional documentation that highlights and describes how your offering is equal in accordance with FAR Clause 52.211-6.

PRICE PROPOSAL
The Offeror shall prepare a price proposal that contains all information necessary to allow for a comprehensive evaluation of the prices quoted. Specifically, your quote must include the following: Federal Tax Identification Number (TIN); Data Universal Numbering System (DUNS) Number; and Business Size (e.g., small or large).